New data confirms prior test results that Volition's novel blood test can accurately detect colorectal cancer and reduce
colonoscopies
NAMUR, Belgium, May 9, 2017 /PRNewswire/ -- At the Digestive
Disease Week 2017 (DDW) in Chicago, VolitionRx Limited (NYSE MKT: VNRX) presented results
that continue to show that the Nu.QTM Colorectal Cancer Screening Triage Test reduces the total number of
colonoscopy referrals while maintaining high sensitivity for cancer detection.
"We have successfully completed this key clinical milestone in the launch of our Nu.QTM Triage product. This
study, with the total cohort totalling just under 8000 subjects demonstrates that the Nu.QTM Triage test was
able to prevent 24.5% of colonoscopies and detect almost 95% of colorectal cancers and 87.9% of high-risk adenomas. It further
strengthens the case for the Nu.QTM Colorectal Cancer Screening Triage test to be incorporated into
colorectal cancer screening programs," said Louise Day, Chief Marketing and Communications Officer
at Volition.
Professor Hans Jorgen Nielsen from Hvidovre Hospital, University of
Copenhagen, commented, "These results, from a very large data set, confirm that the Nu.QTM Triage test has
the potential to accelerate the diagnosis of colorectal cancer, by reducing the number of unnecessary colonoscopies being
performed thereby allowing more people to be screened quickly and effectively."
The presentation from the DDW can be found and downloaded at www.volitionrx.com
About Volition
Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately
diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying
and measuring nucleosomes in the bloodstream or other bodily fluid -- an indication that disease is present.
As cancer screening programs become more and more widespread, our products aim to help to diagnose a range of cancers quickly,
simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to
improve their quality of life.
Volition's research and development activities are currently centered in Belgium, with
additional offices in London, New York, Texas and Singapore, as the company focuses on bringing its diagnostic
products to market first in Europe, then in the U.S. and ultimately, worldwide.
For more information about Volition, visit Volition's website (http://www.volitionrx.com) or connect with us via:
Twitter: https://twitter.com/volitionrx
LinkedIn: https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx
The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference
into this document and should not be considered part of this document. The addresses for Volition's website, Twitter,
LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.
Media / Investor Contacts
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks
and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking
statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates,"
"optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify
forward-looking statements. These forward-looking statements relate to the effectiveness of Volition's bodily-fluid-based
diagnostic tests as well as Volition's ability to develop and successfully commercialize such test platforms for early detection
of cancer. Volition's actual results may differ materially from those indicated in these forward-looking statements due to
numerous risks and uncertainties. For instance, if we fail to develop and commercialize diagnostic products, we may be unable to
execute our plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory
clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to
accept the products in Volition's development pipeline or any other diagnostic products Volition might develop; Volition will
face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the
diagnostics market and its rapid technological change; and other risks identified in Volition's most recent Annual Report on Form
10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange
Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in
part, on assumptions made by management. These statements are not guarantees of future performance and involve risks,
uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release,
and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect
future events or circumstances.
Nucleosomics®, NuQ®, Nu.QTM and HyperGenomics® and their respective logos are
trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names
referred to in this press release are the property of their respective owners.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/volitionrx-limited-announces-final-results-from-8000-patient-clinical-trial-in-denmark-to-evaluate-the-performance-of-its-nuqtm-triage-test-300454011.html
SOURCE VolitionRx Ltd